FDG-PET/CT and prediction of anti-PD-1/PD-L1 antibody in lung cancer

Usefulness of FDG-PET/CT to predict the response after anti-PD-1/PD-L1 antibody in patients with advanced non-small cell lung cancer: a multi-institutional study - FDG PD-1/PD-L1 Study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTs031180036

Enrollment

Registered

2018-11-01

Start date

2018-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung cancer Lung cancer

Interventions

All patients undergo FDG-PET/CT before and 4 weeks and 9weeks after initiation of anti-PD-1/PD-L1 antibody therapy.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Pathologically confirmed advanced non-small cell lung cancer (NSCLC) 2)Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 3)Patient with evaluable lesion based on RECIST 4)Written informed consent

Exclusion criteria

Exclusion criteria: 1)Pregnant woman 2)Patients with obvious interstitial pneumonia or pulmonary fibrosis in the chest X-ray. 3)Patients with collagen vascular disease or autoimmune diseases 4)Other cases attending physician it is determined unsuitable for registration of the study

Design outcomes

Primary

Measure	Time frame
1)Changeing of SUVmax, MTV and TLG, and the efficacy of anti-PD-1/PD-L1 antibody such as nivolumab or pembrolizumab. 2)Evaluation after 4weeks and 9weeks from administration of anti-PD-1/PD-L1 antibody.	—

Secondary

Measure	Time frame
Overall survival and progression-free survival	—

Contacts

Public ContactOu Yamaguchi

Saitama Medical University

ouyamagu@saitama-med.ac.jp+81-42-984-4111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026